Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count.

Abstract

Linezolid was approved by the Food and Drug Administration for the treatment of serious infections. However, patients with serious frequently develop shock, and it is currently elusive whether shock affects the pharmacokinetics of linezolid. The aim of the present study was to explore whether the pharmacokinetics of linezolid are different among patients with various types of shock or patients without shock and whether potential confounders are involved in their outcomes. A population pharmacokinetic analysis using a non-linear mixed-effects model was performed to examine the pharmacokinetics of patients with different types of shock or patients without shock. The pharmacokinetics of linezolid in patients with different types of shock or patients without shock was described by a one-compartment model. In our results, the patients with different types of shock or patients without shock demonstrated no differences in pharmacokinetics, whereas the platelet count was identified as a significant influencing factor. The results demonstrated that the pharmacokinetics of linezolid exhibited no significant differences among patients with different types of shock or patients without shock, whereas the platelet count significantly affected the clearance rate of linezolid.